‘GLP diet drug’ directory
- See Also
- Links
- “The Bio-Pirate’s Guide to GLP-1 Agonists [BMI 28 → 22]”, quiet_NaN 2026
- “Could Weight Loss Drugs Turn Fat Cats Into Svelte Ozempets? GLP-1 Drugs for Pets Could Be the next Frontier for the Blockbuster Weight Loss and Diabetes Drugs”, Anthes 2025
- “Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice”, Gasoyan et al 2025
- “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment”, Wharton et al 2025
- “Everyone Has a Chinese Peptide Dealer Now: At One San Francisco Company [Superpower], Free Peptide Injections Are Offered to the Whole Staff on Fridays.”, Stone 2025
- “Glucagon-Like Peptide-1 Receptor Agonists As Emerging Therapeutics in Bipolar Disorder: a Narrative Review of Preclinical and Clinical Evidence”, Llach et al 2025
- “How GLP-1s Are Breaking Life Insurance: Patients Look Healthy on Paper. Two Years Later, They’re High-Risk Again”, Sharma 2025
- “Lilly’s Oral GLP-1, Orforglipron, Demonstrated Statistically-Significant Efficacy Results and a Safety Profile Consistent With Injectable GLP-1 Medicines in Successful Phase 3 Trial”, Lilly & Company 2025
- “Glucagon-Like Peptide-1 Receptor Activation and Mental Health: a Drug-Target Mendelian Randomization Study”, Yang et al 2025
- “Dozens of New Obesity Drugs Are Coming: These Are the Ones to Watch”
- “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity”, Rodriguez et al 2025
- “Mapping the Effectiveness and Risks of GLP-1 Receptor Agonists”, Xie et al 2025
- “Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Alleviates Gut Inflammation in Mice”, Hammoud et al 2024
- “New Drug MariTide Causes 20% Weight Loss in Early Amgen Results: The Drug, Which Is Delivered in a Monthly Injection, Is Some Time Away from Being Sold”, Kolata 2024
- “The Benefits of GLP-1 Drugs beyond Obesity”, Drucker 2024
- “Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”, Klotsman et al 2024
- “Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
- “Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
- “GLP-1, Parkinson’s Disease, and Neuroprotection”, Standaert 2024
- “Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”, Sadri 2023
- “Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
- “Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
- atrupar @ "2023-07-20"
- “Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
- “Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
- “Glucagon-Like Peptide-1 Receptor Agonists to Expand the Healthy Lifespan: Current and Future Potentials”
- “The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
- “The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
- “Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases”
- “Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats”, Klotsman et al 2021
- “Glycemic Variability in Newly Diagnosed Diabetic Cats Treated With the Glucagon-Like Peptide-1 Analogue Exenatide Extended Release”, Krämer et al 2020
- “Safety and Efficacy Assessment of a GLP-1 Mimetic: Insulin Glargine Combination for Treatment of Feline Diabetes Mellitus”, Scuderi et al 2018
- “Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Campbell 2012
- “The GLP-1 Mimetic Exenatide Potentiates Insulin Secretion in Healthy Cats”, Gilor et al 2011
- “Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients”, Nauck et al 1993
- “Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach”, Ørskov et al 1988
- “GLP-1 Receptor Agonists’ Impact on Cardio-Renal Outcomes and Mortality in T2D With Acute Kidney Disease”
- “Could Danuglipron Be the Next Ozempic in Pill Form?”
- “GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity”
- “Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes”
- “Doctors Test the Limits of What Obesity Drugs Can Fix”
- “Amateur Athletes Are Turning to Ozempic to Raise Their Game”
- Sort By Magic
- Wikipedia (2)
- Miscellaneous
- Bibliography
See Also
Links
“The Bio-Pirate’s Guide to GLP-1 Agonists [BMI 28 → 22]”, quiet_NaN 2026
“Could Weight Loss Drugs Turn Fat Cats Into Svelte Ozempets? GLP-1 Drugs for Pets Could Be the next Frontier for the Blockbuster Weight Loss and Diabetes Drugs”, Anthes 2025
“Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice”, Gasoyan et al 2025
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment”, Wharton et al 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
“Everyone Has a Chinese Peptide Dealer Now: At One San Francisco Company [Superpower], Free Peptide Injections Are Offered to the Whole Staff on Fridays.”, Stone 2025
“Glucagon-Like Peptide-1 Receptor Agonists As Emerging Therapeutics in Bipolar Disorder: a Narrative Review of Preclinical and Clinical Evidence”, Llach et al 2025
“Lilly’s Oral GLP-1, Orforglipron, Demonstrated Statistically-Significant Efficacy Results and a Safety Profile Consistent With Injectable GLP-1 Medicines in Successful Phase 3 Trial”, Lilly & Company 2025
“Glucagon-Like Peptide-1 Receptor Activation and Mental Health: a Drug-Target Mendelian Randomization Study”, Yang et al 2025
“Dozens of New Obesity Drugs Are Coming: These Are the Ones to Watch”
Dozens of new obesity drugs are coming: these are the ones to watch
“Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity”, Rodriguez et al 2025
“Mapping the Effectiveness and Risks of GLP-1 Receptor Agonists”, Xie et al 2025
Mapping the effectiveness and risks of GLP-1 receptor agonists
“Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Alleviates Gut Inflammation in Mice”, Hammoud et al 2024
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
“New Drug MariTide Causes 20% Weight Loss in Early Amgen Results: The Drug, Which Is Delivered in a Monthly Injection, Is Some Time Away from Being Sold”, Kolata 2024
“The Benefits of GLP-1 Drugs beyond Obesity”, Drucker 2024
“Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”, Klotsman et al 2024
“Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
Functional and multi-omic aging rejuvenation with GLP-1R agonism
“Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
“GLP-1, Parkinson’s Disease, and Neuroprotection”, Standaert 2024
GLP-1, Parkinson’s Disease, and Neuroprotection :
View PDF:
“Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”, Sadri 2023
Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs
“Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
“Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
atrupar @ "2023-07-20"
“Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
“Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead :
View PDF:
“Glucagon-Like Peptide-1 Receptor Agonists to Expand the Healthy Lifespan: Current and Future Potentials”
“The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
“The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
“Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases”
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
“Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats”, Klotsman et al 2021
“Glycemic Variability in Newly Diagnosed Diabetic Cats Treated With the Glucagon-Like Peptide-1 Analogue Exenatide Extended Release”, Krämer et al 2020
“Safety and Efficacy Assessment of a GLP-1 Mimetic: Insulin Glargine Combination for Treatment of Feline Diabetes Mellitus”, Scuderi et al 2018
“Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Campbell 2012
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
“The GLP-1 Mimetic Exenatide Potentiates Insulin Secretion in Healthy Cats”, Gilor et al 2011
The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats
“Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients”, Nauck et al 1993
“Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach”, Ørskov et al 1988
“GLP-1 Receptor Agonists’ Impact on Cardio-Renal Outcomes and Mortality in T2D With Acute Kidney Disease”
“Could Danuglipron Be the Next Ozempic in Pill Form?”
“GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity”
“Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes”
“Doctors Test the Limits of What Obesity Drugs Can Fix”
“Amateur Athletes Are Turning to Ozempic to Raise Their Game”
Sort By Magic
Annotations sorted by machine learning into inferred 'tags'. This provides an alternative way to browse: instead of by date order, one can browse in topic order. The 'sorted' list has been automatically clustered into multiple sections & auto-labeled for easier browsing.
Beginning with the newest annotation, it uses the embedding of each annotation to attempt to create a list of nearest-neighbor annotations, creating a progression of topics. For more details, see the link.
glycemic-control
long-term-drug
obesity-treatment
glp-receptor
Wikipedia (2)
Miscellaneous
/doc/longevity/glp/2025-wharton-figure1-orforglipronweightlosscurves.jpg/doc/longevity/glp/2017-schneider.pdf:View PDF:
https://edition.cnn.com/2024/05/08/health/ozempic-babies-pregnancy/index.htmlhttps://journals.sagepub.com/doi/full/10.1177/1098612X16660441https://marginalrevolution.com/marginalrevolution/2024/07/the-economics-of-glp-1.htmlhttps://trevorklee.substack.com/p/glp-1-and-gip-agonism-and-antagonismhttps://www.annualreviews.org/content/journals/10.1146/annurev-med-043021-014919
Bibliography
2025-wharton.pdf: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment”,2025-llach.pdf: “Glucagon-Like Peptide-1 Receptor Agonists As Emerging Therapeutics in Bipolar Disorder: a Narrative Review of Preclinical and Clinical Evidence”,https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-024-04051-6: “Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”,2024-meissner.pdf: “Trial of Lixisenatide in Early Parkinson’s Disease”,2023-sadri.pdf: “Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”,2023-frias-2.pdf: “Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”,https://pmc.ncbi.nlm.nih.gov/articles/PMC8144329/: “Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats”,